Scolaris Content Display Scolaris Content Display

Interventions for antipsychotic‐induced amenorrhoea

Referencias

Additional references

Adams 2014

Adams CE, Awad GA, Rathbone J, Thornley B, Soares‐Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3; PUBMED: 24395698]

Altman 1996

Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.

Bargiota 2013

Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV. The effects of antipsychotics on prolactin levels and women’s menstruation. Schizophrenia Research and Treatment 2013;2013:10. [DOI: 10.1155/2013/502697]

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.

Boissel 1999

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106]

Bushe 2007

Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. Journal of Psychopharmacology 2007;21(7):768‐73.

Cavallaro 2004

Cavallaro R,  Cocchi F,  Angelone SM,  Lattuada E,  Smeraldi E. Cabergoline treatment of risperidone‐induced hyperprolactinemia: a pilot study. Journal of Clinical Psychiatry 2004;65(2):187‐90.

David 2013

Klein DA, Poth MA. Amenorrhea: an approach to diagnosis and management. American Family Physician 2013;87(11):781‐8.

Deeks 2000

Deeks J. Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.

Divac 2014

Divac N, Prostran M, Jakovcevski I, Cerovac N. Second‐generation antipsychotics and extrapyramidal adverse effects. BioMed Research International 2014;2014:6 pages.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9.

Donner 2002

Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971‐80.

Duncan 1995

Duncan D. Treatment of psychotropics induced hyperprolactinaemia. Psychiatry Bulletin 1995;19:755‐7.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34.

Elbourne 2002

Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.

Finny 2005

Finny P, Tharyan P, Thomas N. Role of jasmine flower extract in management of antipsychotic medication induced amenorrhoea. International Endocrinology Conference, 2005, Qatar. 2005.

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10.

Gulliford 1999

Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876‐83.

Haddad 2004

Haddad PM, Wieck A. Antipsychotic‐induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291‐314. [PUBMED: 15456328]

Hammer 1998

Hammer MB, Arana GW. Hyperprolactinaemia in antipsychotic treated patients: guidelines for avoidance and management. CNS Drugs 1998;10:209‐22.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.

Higgins 2011a

Higgins JPT, Green S (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.

Higgins 2011b

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.

Kay 1986

Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.

Keller 2002

Keller R, Mongini F. Switch to quetiapine in antipsychotic agent‐related hyperprolactinemia. Neurological Sciences 2002;23(5):233‐5. [PUBMED: 12522680]

Kinon 2003

Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28 Suppl 2:55‐68. [PUBMED: 12650681]

La Torre 2007

La Torre D, Faloni A. Pharmacological causes of hyperprolactinemia. Journal of Therapeutics and Clinical Risk Management 2007;3(5):929‐51.

Lee 2010

Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, et al. Effect of bromocriptine on antipsychotic drug‐induced hyperprolactinemia: eight‐week randomized, single‐blind, placebo‐controlled, multicenter study. Psychiatry and Clinical Neurosciences 2010;64(1):19‐27. [PUBMED: 19968833]

Leon 2006

Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5. [PUBMED: 16905632]

Leucht 2005a

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797]

Leucht 2005b

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856]

Leucht 2013

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatment analysis. Lancet 2013;382(9896):951‐62.

Madhusoodanan 2010

Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics ‐ a review. Human Psychopharmacology 2010;25(4):281‐97.

Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52.

Messias 2007

Messias E, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatric Clinics of North America 2007;30(3):323‐38.

Overall 1962

Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.

Paul 2013

Paul T, Ravan JR, Thomas N, Thomas N, Samuel P, Braganza D. Risperidone associated changes in prolactin and bone mineral density: a study from South India. Endocrine Abstracts 2013;31:17.

Pueskens 2014

Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs March 2014;28(5):421‐53.

Rummel‐Kluge 2010

Rummel‐Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Asenjo‐Lobos C, et al. Head‐to‐head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta‐analysis. Schizophrenia Research 2010;123(2‐3):225‐33.

Schünemann 2011

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Seeman 2009

Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophrenia Bulletin 2009;35(5):937‐48.

Shim 2007

Shim JC,  Shin JG,  Kelly DL,  Jung DU,  Seo YS,  Liu KH,  et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic‐induced hyperprolactinemia: a placebo‐controlled trial. American Journal of Psychiatry 2007;164(9):1404‐9.

Smith 2002

Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic‐induced hyperprolactinemia on the hypothalamic pituitary gonadal axis. Journal of Clinical Psychopharmacology 2002;22:109‐14.

Staller 2006

Staller J. The effect of long term antipsychotic on prolactin. Journal of Child and Adolescent Psychopharmacology 2006;16:317‐26.

Sterne 2011

Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.

Turkington 1972

Turkington RW. Human prolactin: an ancient molecule provides new insights for clinical medicine. American Journal of Medicine 1972;53(4):389‐94.

Turner 2007

Turner T. Chlorpromazine: unlocking psychosis. BMJ (Clinical research ed.) 2007;334(Suppl 1):s7. [PUBMED: 17204765]

Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PG. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii‐92.

Wieck 2003

Wieck A, Haddad PM. Antipsychotic‐induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. British Journal of Psychiatry 2003;182:199‐204. [PUBMED: 12611781]

Wistedt 1981

Wistedt B, Wiles D, Kolakowska T. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1981;1(8230):1163. [PUBMED: PMID: 6112518]

Xia 2009

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.

Yuan 2008

Yuan HN,  Wang CY,  Sze CW,  Tong Y,  Tan QR,  Feng XJ,  et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone‐induced hyperprolactinemia in patients with schizophrenia. Journal of Clinical Psychopharmacology 2008;28(3):264‐370.